



News release
June 03rd 2021

HEMOSTATIC IMPLANT PATCH FROM GATT (FIBROLINE® INSIDE) UNDERGOES SUCCESSFUL FIRST-IN-MAN

The Dutch medical device startup GATT Technologies has announced the successful first-in-man of its lead product GATT-Patch used to resolve bleeding in a patient undergoing liver resection surgery, a study led by Radboud university medical center Nijmegen (Radboudumc). GATT-Patch is a flexible, fibrous sheet, highly efficiently dry impregnated with synthetic activated POx-polymers making use of Fibroline's technology.

This first patient marks the start of a multicenter clinical trial that will be conducted by three leading academic medical centers in the Netherlands: Radboudumc, The University Medical Center Groningen and Erasmus Medical Centrum Rotterdam according to a recent news release: [GATT announces first-in-man use of 'GATT-Patch', a hemostatic sealant patch, by Radboud university medical center Nijmegen | Markets Insider \(businessinsider.com\)](#)

Between GATT founder and CTO, Dr. Johan Bender and the French start-up Fibroline in Lyon, there has been an ongoing constructive collaboration to implement and optimize POx-polymer impregnation using Fibroline's patented technologies. Geert van Gansewinkel, CEO comments with enthusiasm: *"Based on our synthetic polymer technology, we are convinced of the opportunities of our platform. All pre-clinical work performed in the past years has confirmed safety and superior performance of GATT-Patch. It is very exciting to now see our lead product used in patients, which will give us vital data regarding the safety and performance of GATT-Patch in a clinical setting."*

"We have enjoyed the competence and ability to act fast by the GATT team and think it is one of the main advantages of small teams like GATT and Fibroline: short communication lines and ability to act fast. It has been particularly important for us to be involved in R&D with such potential to improve life-saving surgical procedures. We are involved in other medical use projects, but this is a milestone as the first device that is implantable with Fibroline® Inside." said Fibroline CEO, Jérôme Ville, *"We are privileged to have such a competent partner as GATT"*, he added.

FIBROLINE® INSIDE IS MAKING INROADS IN THE MEDICAL FIELD

"Our technology portfolio has been optimized over the last year to meet Medtech standards and we are now in a position to integrate our solutions into scaled up cleanroom solutions. For example, we are able to guaranty a very clean powder processing and avoid any cross

contamination between the different formulations, while obtaining the desired powder distribution into the porous media. This allows us to work with progressively more challenging customers in many areas of medical and hygienic use.” said Nancy Hummel, in charge of the Medtech product developments at Fibroline.

In addition to the recently announced first-in-man test of GATT-Patch by GATT Technologies, Fibroline has another medical product in regulatory process cooperation with a strategic partner aiming US launch late 2022.



Press contact:

GATT: Geert van Gansewinkel – CEO, g.vangansewinkel@gatt-tech.com

FIBROLINE: Jérôme Ville – CEO, jville@fibroline.com & Nancy Hummel – Medtech Project manager, nhummel@fibroline.com